Real-world usage of anti-seizure medications

Patients with epilepsy face elevated arrhythmia risk, and some anti-seizure medications (ASMs) may worsen that risk; the FDA issued a safety alert for lamotrigine over potential proarrhythmic concerns from lab findings, underscoring the need for deeper investigation. A biotech firm used Truveta Data to examine real-world arrhythmia rates among epilepsy patients, drawing on clinical notes to investigate ASM-related cardiac safety. The page states the work yielded "new insights into ASM-related cardiac risks, helping to inform clinical decision-making and future research," but does not provide specific numerical findings on the visible page.

The customer is anonymised in Truveta’s own case study — not withheld by us.

Truveta is a real-world-data company owned by a consortium of major US health systems, supplying daily-updated de-identified EHR data and a genomic-linkage research program.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.